Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Oct 24

PMID 30349382

Citations 9

Authors

Mengting Tong

Jing Wang

Wenting He

Yanling Wang

Hongming Pan

Da Li

Hongliang Zhang

Affiliations

Soon will be listed here.

Abstract

The development of immune checkpoint inhibitors represented by PD-1 and PD-L1 has provided new hope for the treatment of advanced cancer patients. However, there are no effective predictive biomarkers, which have caused many limitations to the clinical application of immune checkpoint inhibitors. This paper combines recent domestic and international research as well as clinical trials to discuss the current status and progress of PD-L1 expression as a biomarker for tumor immunotherapy and also to discuss whether tumor mutation burden, tumor-infiltrating lymphocytes, tumor cell gene expression profiling, or peripheral blood markers would be a potential predictive biomarker for novel tumor immunotherapy. So, a brief review on this hot topic of predictive biomarkers for tumor immunotherapy is conducted.

Citing Articles

to Evaluate the Tumor Immune Microenvironment and Clinical Prognosis in Glioma.

Qu S, Liu J, Wang H Front Immunol. 2021; 12:648416.

PMID: 33889156 PMC: 8056259. DOI: 10.3389/fimmu.2021.648416.

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.

Tomita Y, Oronsky B, Abrouk N, Cabrales P, Reid T, Lee M Transl Lung Cancer Res. 2021; 10(1):274-278.

PMID: 33569311 PMC: 7867783. DOI: 10.21037/tlcr-20-359.

Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.

Kang B, Chau I ESMO Open. 2020; 5(4).

PMID: 32817133 PMC: 7440716. DOI: 10.1136/esmoopen-2020-000791.

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.

Taylor M, Hughes A, Walton J, Coenen-Stass A, Magiera L, Mooney L J Immunother Cancer. 2019; 7(1):328.

PMID: 31779705 PMC: 6883640. DOI: 10.1186/s40425-019-0794-7.

Management of recurrent or refractory Ewing sarcoma: A systematic review of phase II clinical trials in the last 15 years.

Xu J, Xie L, Sun X, Dong S, Tang X, Guo W Oncol Lett. 2019; 18(1):348-358.

PMID: 31289506 PMC: 6540207. DOI: 10.3892/ol.2019.10328.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Schatton T, Scolyer R, Thompson J, Mihm Jr M . Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2013; 1102:287-324. DOI: 10.1007/978-1-62703-727-3_16. View

Zheng C, Zheng L, Yoo J, Guo H, Zhang Y, Guo X . Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017; 169(7):1342-1356.e16. DOI: 10.1016/j.cell.2017.05.035. View

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

Jacquelot N, Roberti M, Enot D, Rusakiewicz S, Ternes N, Jegou S . Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017; 8(1):592. PMC: 5605517. DOI: 10.1038/s41467-017-00608-2. View

Rakic A, Beaudry P, Mahoney D . The complex interplay between neutrophils and cancer. Cell Tissue Res. 2018; 371(3):517-529. DOI: 10.1007/s00441-017-2777-7. View

Wolf G, Chepeha D, Bellile E, Nguyen A, Thomas D, McHugh J . Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol. 2014; 51(1):90-5. PMC: 4268429. DOI: 10.1016/j.oraloncology.2014.09.006. View

Mahoney K, Rennert P, Freeman G . Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015; 14(8):561-84. DOI: 10.1038/nrd4591. View

10.

Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T . Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014; 25(10):1935-1940. DOI: 10.1093/annonc/mdu242. View

11.

Peng W, Chen J, Liu C, Malu S, Creasy C, Tetzlaff M . Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2015; 6(2):202-16. PMC: 4744499. DOI: 10.1158/2159-8290.CD-15-0283. View

12.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K . Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017; 28(7):1532-1539. DOI: 10.1093/annonc/mdx183. View

13.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

14.

Martens A, Wistuba-Hamprecht K, Foppen M, Yuan J, Postow M, Wong P . Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin Cancer Res. 2016; 22(12):2908-18. PMC: 5770142. DOI: 10.1158/1078-0432.CCR-15-2412. View

15.

Boussiotis V . Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med. 2016; 375(18):1767-1778. PMC: 5575761. DOI: 10.1056/NEJMra1514296. View

16.

Kythreotou A, Siddique A, Mauri F, Bower M, Pinato D . PD-L1. J Clin Pathol. 2017; 71(3):189-194. DOI: 10.1136/jclinpath-2017-204853. View

17.

Fu J, Kanne D, Leong M, Glickman L, McWhirter S, Lemmens E . STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015; 7(283):283ra52. PMC: 4504692. DOI: 10.1126/scitranslmed.aaa4306. View

18.

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

19.

He H, Qi L, Xiao Y, Hou Y . [Tumor Associated Fibroblasts Promote PD-L1 Expression in Lung Cancer Cells]. Zhongguo Fei Ai Za Zhi. 2017; 20(5):293-297. PMC: 5973068. DOI: 10.3779/j.issn.1009-3419.2017.05.01. View

20.

Li B, Severson E, Pignon J, Zhao H, Li T, Novak J . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17(1):174. PMC: 4993001. DOI: 10.1186/s13059-016-1028-7. View